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Abstract
We have previously reported that MUC4 expression is a poor prognostic factor in various carcinomas. Our previous study
also showed that MUC1 expression in gastric cancers, including the early and advanced stages is a poor prognostic factor. In
the present study, the expression profiles of MUC4 and MUC1 were examined by immunohistochemistry (IHC) using two
anti-MUC4 monoclonal antibodies (MAbs), 8G7 and 1G8, and anti-MUC1 MAb DF3 in 104 gastrectomy specimens of early
gastric adenocarcinoma with submucosal invasion (pT1b2), including 197 histological subtype lesions. Before the IHC study
of the human specimens, we evaluated the specificity of the two MAbs by Western blotting and IHC of two MUC4 mRNA
expressing gastric cancer cell lines. MAb 8G7 reacted clearly, whereas MAb 1G8 did not show any reactivity, in either
Western blotting or IHC. In the IHC of the gastric cancers, the expression rates of MUC4/8G7 detected by MAb 8G7, MUC4/
1G8 detected by MAb 1G8 and MUC1/DF3 detected by MAb DF3 in well differentiated types (70%, 38/54; 67%, 36/54; 52%,
28/54) were significantly higher than those in poorly differentiated types (18%, 10/55; 36%, 20/55; 13%, 7/55) (P,0.0001;
P= 0.0021; P,0.0001), respectively. The MUC4/8G7 expression was related with lymphatic invasion (r = 0.304, P= 0.033). On
the other hand, the MUC4/1G8 expression was related with lymphatic invasion (r = 0.395, P= 0.001) and lymph node
metastasis (r = 0.296, P= 0.045). The MUC1/DF3 expression was related with lymphatic invasion (r = 0.357, P= 0.032) and
venous invasion (r = 0.377, P= 0.024). In conclusion, the expression of MUC4 as well as MUC1 in early gastric cancers is
a useful marker to predict poor prognostic factors related with vessel invasion.
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Introduction
Gastric cancer is the fourth most common cancer worldwide
and more than 90% of gastric cancers are adenocarcinomas [1].
Recently, in Japan, early detection by the routine endoscopic
examination in the gastroenterology clinics has resulted accurate
diagnoses and effective surgical or endoscopic treatments, resulting
in a relatively better prognosis. In the analysis of 11,261 patients
with gastric cancer treated by gastric resection, the TNM 5-year
survival rate for stage IA was 91.8% and for stage IB the survival
rate was 84.6% [2]. For the early gastric cancers, an endoscopic
submucosal dissection (ESD) is the first choice treatment in Japan,
but the criteria of the additional surgery including lymph node
dissection after the ESD are still controversial [3].
Our series of immunohistochemistry (IHC) studies for mucin
expression in various human neoplasms have demonstrated that
the expression of the MUC1 mucin (pan-epithelial membrane-
associated mucin) is related with invasive proliferation of the
tumors and poor outcome of the patients, whereas the expression
of the MUC2 mucin (intestinal type secretory mucin) is related
with the non-invasive proliferation of the tumors and a favorable
outcome for the patients [4,5]. Our previous study showed that
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MUC1 expression in gastric cancers is a poor prognostic factor
[6].
MUC4 was first reported as tracheobronchial mucin [7] and is
a membrane-associated mucin [8]. In our study series, the
expression of MUC4 in intrahepatic cholangiocarcinoma, pan-
creatic ductal adenocarcinoma, extrahepatic bile duct carcinoma,
lung adenocarcinoma, and oral squamous cell carcinoma was an
independent factor for poor prognosis and is a useful marker to
predict the outcome of the patients [5,9,10,11,12,13]. Unfortu-
natly, there are few studies of the MUC4 expression profile in
human gastric cancer. In the present study, we examined the
expression profiles of MUC4 as well as MUC1 in early gastric
cancer tissues, and found that MUC4 and MUC1 expression in
the early gastric cancers would become poor prognostic factors by
lymph vessel invasion, blood vessel invasion and lymph node
metastasis.
As anti-MUC4 monoclonal antibodies (MAbs), 8G7 and 1G8,
are known to detect different sites of MUC4 molecule. The MAb
8G7 recognizes a tandem repeat sequence
(STGDTTPLPVTDTSSV) of the human MUC4a subunit [14].
The MAb 1G8 is raised against the rat sequence (rat ASGP-2), and
recognizes an epitope on the rat ASGP-2 subunit, which
corresponds to the human MUC4b subunit, and shows a cross
reactivity with human samples [15]. Thus, a special attention was
paid to the comparison of two anti-MUC4 MAbs by Western
blotting and IHC of two gastric cancer cell lines, before the IHC
study of human gastric cancer tissues. Moreover, since there is
controversy regarding the prognostic significance of these anti-
MUC4 MAbs, a literature review of MUC4 expression in various
cancers was also performed.
Materials and Methods
Patients and Tissue Samples
Gastrectomy specimens of 104 early gastric cancers, which show
submucosal invasion, pT1b2, with or without lymph node
metastasis, were retrieved from the file between 1994 and 2008
of the Kagoshima-shi Medical Association Hospital. The mean
age of the patients was 65.7 (S.D., 9.8; range, 39–92 years; median
age, 66 years); 64 cases were male, and 40 cases were female. This
Study was conducted in accordance with the guiding principles of
the Declaration of Helsinki, and approved by the Ethics
Committee for Kagoshima-shi Medical Association Hospital
(KMAH 2011-02-02). Informed, written consent was obtained
from all patients. In the cases with more than two histological types
mixed in one lesion, each histological pattern was evaluated
independently, according to the Japanese Classification of Gastric
Carcinoma (JCGC) [16].
Evaluation of Monoclonal Antibodies for MUC4
Cells and culture conditions. Human gastric cancer cell
lines (SNU-16 and NCI-N87) and pancreatic cancer cell lines
(PANC1 and CAPAN1) were purchased from the American Type
Culture Collection (Manassas, VA). Both gastric cancer cells were
maintained in RPMI-1640 (Sigma-Aldrich, St Louis, MO);
PANC1 cells were maintained in DMEM (Sigma-Aldrich);
Figure 1. The difference in antibody specificity between anti-human MUC4 monoclonal antibodies (MAbs), 8G7 and 1G8. A: MUC4
mRNA was detected in the two gastric cancer cell lines, SNU-16 and NCI-N87. PANC1 and CAPAN1 cells were used as a negative and positive control,
respectively. B: Cell lysates of SNU-16 and NCI-N87 were immunoblotted and detected by the indicated antibodies, respectively. A-tubulin served as
a loading control. C: Formalin-fixed SNU-16 and NCI-N87 cells were processed for immunocytochemistry using the MAbs, 8G7 and 1G8, respectively.
Original magnification6400.
doi:10.1371/journal.pone.0049251.g001
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Capan1 cells were maintained in DMEM/F-12 (Sigma-Aldrich).
All media were supplemented with 10% fetal bovine serum
(GIBCO, Breda, The Netherlands) and 100 U/mL penicillin/
100 mg/mL streptomycin (Sigma-Aldrich). All cells were incubat-
ed in 5% CO2 at 37uC and maintained at sub-confluent levels.
RNA extraction and RT-PCR. Total RNA was extracted
from the cells using the RNeasy mini kit (Qiagen, Hilden,
Germany) and quantified by NanoDrop ND-1000 spectropho-
tometer. The obtained mRNA (2ug) was reverse transcribed to
cDNA with the High Capacity RNA to cDNA kit (Applied
Biosystems, Foster City, CA). The following primers were designed
for the subsequent PCR: MUC4, 59- TGGGACGATGCT-
GACTTCTC-39, 59-CCCCGTTGTTTGTCATCTTTC-39;
ACTB, 59-CTCTTCCAGCCTTCCTTCCTG-39, 59-GAAG-
CATTTGCGGTGGACGAT-39. PCR was performed with the
AmpliTaq Gold Fast PCR Master Mix (Applied Biosystems)
following the manufacturer’s protocol.
Protein extraction and western blotting. Total cell lysates
were prepared using RIPA buffer containing protease inhibitor
cocktail (Nacalai Tesque, Kyoto, Japan). The protein concentra-
tion was measured by the BCA assay (Thermo Scientific,
Rockford, IL). An equal amount of protein lysate was resolved
on 2% agarose gel containing SDS and passively transferred onto
PVDF membrane overnight at room temperature. Membranes
were blocked with 1% skim milk/PBST over 2 hours and
subjected to the standard immunodetection procedure using
specific primary antibodies. The primary antibodies are as follows:
anti-human MUC4 MAb 8G7 (1:1000, generated by Dr. Surinder
K. Batra, University of Nebraska Medical Center, Omaha, NE)
and 1G8 (1:1000, purchased from Invitrogen, Camarillo, CA), and
anti-human a-tubulin MAb DM1A (1:2,000, Sigma-Aldrich).
Immunocytochemistry for cultured cells. For MUC4
staining in cultured cells, cells were seeded in 8-chamber slides
(Becton Dickinson and Company, Franklin lakes, NJ) and
incubated for overnight. Cells were fixed with 3.7% formaldehyde
for 10min at room temperature and stained with MAb 8G7
(1:24,000) and MAb 1G8 (1:4,000) overnight at 4uC, respectively.
Signal detection was performed by an immunoperoxidase method
using a Vectastain Elite ABC kit (Vector Laboratories, Inc.,
Burlingame, CA) according to the manufacturer’s instructions.
Immunohistochemistry for Human Tissues
IHC for human gastric carcinomas was done by using the
following antibodies in the maximum cut sections in each tumor.
MUC4 was detected by two MAbs, 8G7 and 1G8. For the
comparative study, MUC1 expression was also examined by MAb
DF3 (mouse IgG, TFB, Tokyo, Japan). IHC was performed by the
immunoperoxidase method as follows. Antigen retrieval was
Figure 2. Expression patterns of MUC4/8G7, MUC4/1G8 and MUC1/DF3 in each histological type of gastric carcinoma. Hematoxylin-
eosin (HE) (A), MUC4/8G7 (B), MUC4/1G8 (C) and MUC1/DF3 (D) in papillary adenocarcinoma (pap). HE (E), MUC4/8G7 (F), MUC4/1G8 (G) and MUC1/
DF3 (H) in well differentiated tubular adenocarcinoma (tub1). HE (I), MUC4/8G7 (J), MUC4/1G8 (K) and MUC1/DF3 (L) in moderately differentiated
tubular adenocarcinoma (tub2). HE (M), MUC4/8G7 (N), MUC4/1G8 (O) and MUC1/DF3 (P) in mucinous carcinomas (muc). HE (Q), MUC4/8G7 (R),
MUC4/1G8 (S) and MUC1/DF3 (T) in solid type poorly differentiated adenocarcinoma (por1). HE (U), MUC4/8G7 (V), MUC4/1G8 (W) and MUC1/DF3 (X)
in non-solid type poorly differentiated adenocarcinoma (por2). HE (Y), MUC4/8G7 (Z), MUC4/1G8 (a) and MUC1/DF3 (b) in signet-ring cell carcinoma
(sig). MUC4/8G7 was expressed in the cytoplasm of pap (B), tub1 (F) and tub2 (J), but not in muc (N), por1 (R), por2 (V) nor sig (Z). MUC4/1G8 was
expressed mainly at the cell apexes of pap (C), tub1 (G) and tub2 (K), but not in muc (O), por1 (S) nor por2 (W). MUC4/1G8 expression was seen in the
intracytoplasmic mucin substance of sig (a). MUC1/DF3 was expressed mainly at the cell apexes tub2 (L), but not expressed in the cases shown in this
figure (D, H, P, T, X and b). Original magnification6200 (A–H, M–T),6400 (I–L, U–b).
doi:10.1371/journal.pone.0049251.g002
Figure 3. Semiquantitative evaluation of mucin expression in gastric carcinoma for each histological type (negative, none of the
carcinoma cells stained; faint, .0% to ,5% of carcinoma cells stained; 1+, $5% to ,25%; 2+, $25% to ,50%; 3+, $50% to ,75%;
and 4+: $75% stained. The detailed number and percentage of positively stained neoplastic cells using the scoring system were summarized in
Table S1. MUC4/8G7, MUC4/1G8 and MUC1/DF3 expressions were were significantly higher in the well differentiated types (pap+tub1) than in the
poorly differentiated type (por1+por2) (P,0.0001, P=0.0021 and P,0.0001, respectively) (arrows). In tub1, expression rates of MUC4/8G7 and MUC4/
1G8 were significantly higher than that of MUC1/DF3 (P= 0.0106 and P= 0.039, respectively) (*1). In por2, the expression rate of MUC4/1G8 was
significantly higher than that of MUC4/8G7 (P= 0.0286) or that of MUC1/DF3 (P=0.0005) (*2). In sig, the expression rate of MUC4/1G8 was
significantly higher than that of MUC4/8G7 (P= 0.0158) or that of MUC1/DF3 (sig, P= 0.0019) (*3). In the other histolgical types (pap, tub2, muc and
por1), there was no significant difference in the expression rates among MUC4/8G7, MUC4/1G8 and MUC1/DF3.
doi:10.1371/journal.pone.0049251.g003
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performed using CC1 antigen retrieval buffer (pH8.5 EDTA,
10037uC, 30 min., Ventana Medical Systems, Tucson, AZ) for all
sections. Following incubation with the primary antibodies (MAb
MUC4/8G7 diluted 1:3000, 37uC, 32 min.; MAb MUC4/1G8
diluted 1:500, 37uC, 24 min.; MAb MUC1/DF3 diluted 1:50,
37uC, 32 min.) in phosphate buffered saline pH 7.4 (PBS) with 1%
bovine serum albumin, sections were stained on a Benchmark XT
automated slide stainer using a diaminobenzidine detection kit
(ultraView DAB, Ventana Medical Systems). For simplicity,
MUC4/8G7, MUC4/1G8 and MUC1/DF3 are used to indicate
the mucin antigens detected by each antibody.
Scoring of the results and statistical analysis. Four
blinded investigators (Y.T., M.H., M.G. and S.Y.) evaluated the
IHC staining data independently. When the evaluation differed
among the four, a final decision was made by consensus. The
results were evaluated based on the percentage of positively
stained carcinoma cells, and the percentage data were categorized
into six grades using the following scoring system: negative, none
of the carcinoma cells stained; faint, ,5% of carcinoma cells
stained; 1+, $5% to ,25%; 2+, $25% to ,50%; 3+, $50% to
,75%; and 4+: $75% stained. Cases with $5% of carcinoma
cells stained were considered positive. Statistical analysis was
performed by nonparametric methods using EXCEL-Statistics
ver.3 software generated by Hisae Yanai, Faculty of Science,
Saitama University (OMS Publishing, Japan).
Survival of the patients was compared between the group with
positive MUC4/8G7, MUC4/1G8 or MUC1/DF3 expression
and the group with negative expression according the Kaplan-
Meier method, and differences between the survival curves were
tested using the log-rank test. A probability of P,0.05 was
considered statistically significant.
Results
Evaluation of Two Monoclonal Antibodies for MUC4
To investigate the difference in antibody specificity between
8G7 and 1G8, we carried out RT-PCR, Western blotting and
IHC analysis using two gastric cancer cell lines, SNU-16 and NCI-
N87 cells. The MUC4 mRNA was detected in the two gastric
cancer cell lines (Fig. 1A). Consistent with the previous report [14],
our data showed that 8G7 recognized a very high molecular
weight protein (over 500 kD, which was the expected size for
native MUC4). On the contrary, 1G8 does not show any
immunoreactive bands (Fig. 1B). The same result was observed
in the IHC analysis (Fig. 1C).
Immunohistochemical Staining of Gastrectomy
Specimens
Immunohistochemical staining of non-neoplastic gastric
mucosa. In the non-neoplastic mucosa of the cases with gastric
cancer, MUC4/8G7 was expressed sometimes in the cytoplasm of
surface mucous epithelium, and frequently but weakly in the
cytoplasm of fundic and pyloric glands (Figure S1 A and D).
MUC4/1G8 was frequently expressed in the cell apex and
cytoplasm of the surface mucous epithelium, and frequently but
weakly in the cytoplasm of fundic and pyloric glands (Figure S1 B
and E), and was seen constantly at the vascular endothelium.
MUC1/DF3 was sometimes expressed in the surface mucous
epithelium, and always in the fundic glands (particularly intensely
at the cell apexes), but not in the pyloric glands (Figure S1 C and
F).
Immunohistochemical staining of gastric
adenocarcinoma. We examined gastrectomy specimens of
104 early gastric cancers (pT1b2), since we wished to avoid the
major degenerative changes that are frequently seen in advanced
cancer tissues, and to adjust the stage for the accurate comparison
between IHC findings and the clinicopathologic factors.
When more than two histological types were mixed in one lesion
in the gastrectomy specimens of 104 early gastric cancers, each
histological pattern was evaluated independently, according to the
JCGC [16]. Therefore, in the 104 gastrectomy specimens, we
could evaluate 197 carcinoma foci of various histological types in
total.
Among the 197 lesions, there were 15 lesions of papillary
adenocarcinoma (pap) (Figs. 2A–D), 39 of well differentiated
tubular adenocarcinoma (tub1) (Figs. 2E–H), 52 of moderately
differentiated tubular adenocarcinoma (tub2) (Figs. 2I–L), 6 of
mucinous carcinomas (muc) (Figs. 2M–P), 8 of solid type poorly
differentiated adenocarcinoma (por1) (Figs. 2Q–T), 47 of non-solid
type poorly differentiated adenocarcinoma (por2) (Figs. 2U–X)
and 30 of signet-ring cell carcinoma (sig) (Figs. 2Y-b), based on the
context of common histological classification of gastric cancer in
JCGC [16]. According to the context in the WHO classification of
tumours of the stomach [17] as well as that in JCGC [16], pap and
tub1 were classified into ‘‘well-differentiated adenocarcinoma’’,
and por1 and por2 were classified into ‘‘poorly-differentiated
adenocarcinoma’’. The data of the expression rate of MUC4/
8G7, MUC4/1G8 andMUC1/DF3 were summarized in Figure 3.
The detailed number and percentage of positively stained
neoplastic cells using the scoring system were summarized in
Table S1.
Expression profile of MUC4/8G7. Among the 197 adeno-
carcinoma lesions, MUC4/8G7 was expressed in 83 lesions (42%).
MUC4/8G7 showed a significantly higher rate of the positive
expression ($5% of carcinoma cells stained) in well differentiated
types (pap+tub1: 70%, 38/54) than that in poorly differentiated
types (por1+por2: 18%, 10/55) (P,0.0001) (Fig. 3A, arrows).
Table 1. Relationship between expression of MUC4 and
MUC1 and lymphatic invasion (ly), venous invasion (v) or
lymph node metastasis (N).
ly v N
MUC4/8G7 expression r = 0.304 r = 0.280 r = 0.184
P = 0.033 P = 0.083 P = 0.544
MUC4/1G8 expression r = 0.395 r = 0.232 r = 0.296
P = 0.001 P = 0.205 P = 0.045
MUC1/DF3 expression r = 0.357 r = 0.377 r = 0.282
P = 0.032 P = 0.024 P = 0.288
Spearman’s rank-correlation coefficient.
doi:10.1371/journal.pone.0049251.t001
Table 2. Correlation among MUC4/8G7, MUC4/1G8 and
MUC1/DF3.
Comparison Correlation coefficient P value
MUC4/8G7 MUC4/1G8 r = 0.486 P,0.0001
MUC4/8G7 MUC1/DF3 r = 0.267 P = 0.202
MUC4/1G8 MUC1/DF3 r = 0.245 P = 0.269
Spearman’s rank-correlation coefficient.
doi:10.1371/journal.pone.0049251.t002
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MUC4/8G7 was expressed mainly in the cytoplasm of the
neoplastic cells of pap (Fig. 2B), tub1 (Fig. 2F) and tub2 (Fig. 2J), in
the cases with positive expression.
Expression profile of MUC4/1G8. Among the 197 adeno-
carcinoma lesions, MUC4/1G8 was expressed in 95 lesions (48%).
MUC4/1G8 showed significantly higher rates of the positive
expression in well differentiated types (pap+tub1: 67%, 36/54)
than that in poorly differentiated types (por1+por2: 36%, 20/55)
(P=0.0021) (Fig. 3B, arrows). MUC4/1G8 was expressed mainly
at the cell apexes of pap (Fig. 2C), tub1 (Figs. 2G) and tub2
(Fig. 2K), or in the intracytoplasmic mucin substance of sig
(Fig. 2a), in the cases with positive expression.
Expression profile of MUC1/DF3. Among the 197 adeno-
carcinoma lesions, MUC1/DF3 was expressed in 62 lesions (31%).
MUC1/DF3 showed significantly higher rates of the positive
expression in well differentiated types (pap+tub1: 52%, 28/54)
than that in poorly differentiated types (por1+por2: 13%, 7/55)
(P,0.0001) (Fig. 3C, arrows). MUC1/DF3 was expressed mainly
at the cell apexes of pap, tub1 and tub2 (Fig. 2L), in the cases with
positive expression.
Comparison of mucin expression in each histologic
type. In tub1, expression rates of MUC4/8G7 and MUC4/
1G8 were significantly higher than that of MUC1/DF3
(P=0.0106 and P=0.039, respectively) (Fig. 3, *1). In por2, the
expression rate of MUC4/1G8 was significantly higher than that
of MUC4/8G7 (P=0.0286) or that of MUC1/DF3 (P=0.0005)
(Fig. 3, *2). In sig, expression rate of MUC4/1G8 was significantly
higher than that of MUC4/8G7 (P=0.0158) or that of MUC1/
DF3 (sig, P=0.0019) (Fig. 3, *3). In the other histolgical types
(pap, tub2, muc and por1), there was no significant difference in
the expression rates among MUC4/8G7, MUC4/1G8 and
MUC1/DF3 (Fig. 3).
Relationship between MUC4 or MUC1 expression and
lymph vessel invasion, blood vessel invasion and lymph
node metastasis. Semiquantitative evaluation of lymphatic
invasion (ly), venous invasion (v) and lymph node metastasis status
(N) is defined in the JCGC [16]. Lymphatic invasion (ly) was
evaluated as follows; ly0, no lymphatic invasion; ly1, minimal
lymphatic invasion; ly2, moderate lymphatic invasion; and ly3,
marked lymphatic invasion. For the venous invasion (v), similar
evaluation (v0 to v3) was done using elastic staining (Victoria-Blue)
which was added to hematoxylin-eosin staining. The total number
of lymph nodes and the number of involved lymph nodes at each
nodal station (N) were recorded as follows; N0, no regional lymph
node metastasis; N1, metastasis in 1–2 regional lymph nodes; and
N2, metastasis in 3–6 regional lymph nodes. Regional lymph node
metastasis was observed in 55 patients (N1, 41 cases; N2, 14 cases).
There was no significant correlation between the histological types
Table 3. Clinicopathological studies using anti-MUC4 monoclonal antibodies, 8G7 and 1G8.
Organ Carcinoma type Used Antibody
Correlation of MUC4
expression with outcome Reference Ref. No
Oral cavity Squamous cell carcinoma 8G7 Poor Hamada (2012) [9]
Upper aerodigestive tract Squamous cell carcinoma 1G8 Better Weed (2004) [28]
Salivary gland Mucoepidermoid carcinoma 1G8 Better Weed (2004) [27]
Salivary gland Mucoepidermoid carcinoma 1G8 No correlation Handra-Luca (2005) [20]
Salivary gland Mucoepidermoid carcinoma Rabbit polyclonal
(Gut 2000 47:349)
Better Alos (2005) [19]
Thyroid Papillary carcinoma 1G8 No expression of MUC4/1G8 Baek (2007) [25]
Thyroid Papillary carcinoma 1G8 Correlation with small tumor
size and microcarcinoma
subtype,
No comment for outcome
Nam (2011) [23]
Lung Small sized adenocarcinoma 8G7 Poor Tsutsumida (2007) [13]
Lung Non–small cell lung carcinoma 1G8 (Zymed) Better Kwon (2007) [29]
Lung Non–small cell lung carcinoma(NSCLC) 1G8 Better Jeon (2010) [30]
Breast Adenocarcinoma 1G8 No correlation Rakha (2005) [21]
Stomach Adenocarcinoma 8G7 No association with tumor
type, stage or with the
degree of differetiation, No
comment for outcome
Senapati (2008) [18]
Bile duct Intrahepatic cholangiocarcinoma-mass
forming type
8G7 Poor Shibahara (2004) [10]
Bile duct Extrahepatic bile duct carcinoma 8G7 Poor Tamada (2006) [11]
Pancreas Invasive ductal carcinoma 8G7 Poor Saitou (2005) [12]
Pancreas Pancreatobiliary adenocarcinomas 1G8 Poor Westgaard (2009) [31]
Colon Colorectal adenocarcinoma 8G7 Poor Shanmugam (2010) [26]
Ovary Serous, mucinous, endometrioid and
clear cell carcinoma
8G7 No correlation Chauhan (2006) [22]
Prostate Prostate cancer 8G7 Down regulation in prostate
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and lymphatic invasion, venous invasion or lymph node metastasis
status.
In each case, the highest score of the six IHC grades (negative,
faint, 1+, 2+, 3+ or 4+) in the various histological types was
counted as the IHC score in each individual, e.g. ‘‘IHC score 4+’’
for a case with [tub1 score, 3+; tub2 score, 4+]. We evaluated the
correlation between the IHC score and the ly, v and N factors in
each patient. As shown in Table 1, the MUC4/8G7 expression
was related with lymphatic invasion (r = 0.304, P=0.033). The
MUC4/1G8 expression was related with lymphatic invasion
(r = 0.395, P=0.001) and lymph node metastasis (r = 0.296,
P=0.045). The MUC1/DF3 expression was related with
lymphatic invasion (r = 0.357, P=0.032) and venous invasion
(r = 0.377, P=0.024).
Furthermore, we examined the correlation among the IHC
scores of MUC4/8G7, MUC4/1G8 and MUC1/DF3. As shown
in Table 2, there was a correlation between MUC4/8G7 score
and MUC4/1G8 score (r = 0.486, P,0.0001). In contrast, there
was no correlation between MUC4/8G7 score and MUC1/DF3
score (r = 0.267, P=0.202), and there was no correlation between
MUC4/1G8 score and MUC1/DF3 score (r = 0.245, P=0.269).
Relationship between MUC4 or MUC1 expression and
survival. Among the 104 patients, follow up data was obtained
for 87 patients. Median follow up period was 47.5 months (range,
0–193 months). In the 87 patients, one patient died of the gastric
carcinoma 39 months after surgery, one patient showed liver
metastasis but survived for 78 months, and two patients died of
other diseases. In 85 patients excluding two patients died of other
diseases, Kaplan-Meier estimate was tested using the log-rank test.
Between the positive group and negative group (MUC4/8G7+ vs
2, MUC4/1G8+ vs 2 or MUC1/DF3+ vs 2), log-rank test of
overall survival (MUC4/8G7, P= 0.27; MUC4/1G8, P= 0.37;
MUC1/DF3, P= 0.22) and progression-free survival (MUC4/
8G7, P= 0.85; MUC4/1G8, P= 0.23; MUC1/DF3, P= 0.83)
showed no significant differences. Further analysis of 42 patients
survived for more than 5 years also showed no significant
differences.
Discussion
Recently, we have reported that the expression of MUC4 is an
independent poor prognostic factor of pancreatobiliary adenocar-
cinomas [10,11,12] as well as lung adenocarcinoma [13] and oral
squamous cell carcinoma [9]. MUC1 has also been reported to be
a poor prognostic factor in various human neoplasms [4,5]. Our
previous study in gastric cancers, including both early cancers and
advanced cancers demonstrated that MUC1 is a useful prognostic
factor for poor outcome in the patients [6]. In the present study,
the relationship between mucin expression and the patient’s
outcome cannot be evaluated, because the gastric cancers are in
the early stage at pT1b2 and most of the patients have had
a favorable outcome. Nevertheless, the following results were
obtained: (1) The MUC4/8G7, MUC4/1G8 and MUC1/DF3
expressions were related with lymphatic invasion. (2) The MUC4/
1G8 expression was related with lymph node metastasis. (3) The
MU1/DF3 expression was related with venous invasion. In Japan,
ESD is the first choice treatment for early gastric cancers [3].
Examination of MUC4 as well as MUC1 in the ESD specimens
may clarify whether the additional surgery, including lymph node
dissection or frequent follow-up for the metastasis are necessary.
Our previous studies demonstrated that there was no siginificant
correlation between MUC4 expression and MUC1 expression
[10,11,12,13]. Also in the present study of the gastric cancers in
the early stage, there was no siginificant correlation between
expression of MUC4 and MUC1. Both MUC4 and MUC1
expression in the gastric cancers may be related with the poor
prognostic factors, such as lymphatic invasion, venous invasion
and lymph node metastasis, by means of different mechanism.
In the previous study of gastric cancers using MAb 8G7,
Senapati et al. demonstrated that MUC4/8G7 expression was not
associated with tumor type, stage or with the degree of
differentiation [18]. Interestingly, their results showed an 42%
expression rate in the stage I cancers (n = 19), which is in
accordance with our data (MUC4/8G7: 42% and MUC4/1G8:
48%) in the present study examining stage I cancers (n = 104).
However, our study revealed that both MUC4/8G7 and MUC4/
1G8 expressions were different among the histological types, and
were significantly higher in the well differentiated types than in the
poorly differentiated type. MUC1/DF3 expression was also
significantly higher in the well differentiated types than in the
poorly differentiated type. We reported that MUC1 expression
was high in the well differentiated adenocarcinoma in gastric
cancers including advanced cancers, and the high MUC1
expression may affect the survival of patients with well differen-
tiated adenocarcinoma of stomach [6]. The high expression of
MUC4 in the well differentiated adenocarcinoma also may affect
the survival of patients with gastric cancer. In our previous study
[6], the rate of high expression of MUC1/DF3 was significantly
higher in the advanced gastric cancers than that in the early gastric
cancers. The relationship of MUC4 expression with the invasion
of gastric cancers would be an interesting area of study.
There is controversy regarding the prognostic significance of
MUC4/8G7 and MUC4/1G8 expression. Thus, we have
reviewed 19 articles of MUC4 IHC study applied for various
human cancer tissues (Table 3). The significance of MUC4/8G7
and MUC4/1G8 could not be evaluated in 8 of the 19 studies.
One study using polyclonal anti-MIUC4 antibody reported that
MUC4 expression is related to a fovorabel outcome [19], three
studies show no correlation between MUC4 expression and
prognosis [20,21,22], the other three studies did not have any
comments on the correlation between MUC4 expression and
prognosis [18,23,24], and the remaining one study of thyroid
cancer reported no MUC4 expression in the cancer [25]. On the
other hand, in the other 11 articles, there was an apparent
difference of the prognostic significance between MUC4/8G7
expression and MUC4/1G8 expression. Most studies using 8G7,
which was generated against human MUC4, MUC4/8G7
expression is related to aggressive tumor behavior or a poor
outcome in human carcinomas [9,10,11,12,13,26]. In contrast,
most studies using 1G8, which was raised against rat ASGP-2,
described that MUC4/1G8 expression is related to a favorable
outcome [27,28,29,30], although one study of pancreatic adeno-
carcinoma described that MUC4/1G8 expression is related to
poor survival [31]. This clear difference raises the question of
whether 8G7 and 1G8 have essentially different characters. The
MAb 1G8 was raised using rat Muc4 epitope [15]. Human MUC4
and rat Muc4 shows more than 60% peptide sequence similarity
[32], but they are not identical. It is noteworthy that IHC using
MAb 1G8 always shows positive staining in the vascular
endothelium, which is somewhat unusual as the expression of
MUC4 which is one of the members of mucins.
Thus, we evaluated the specificity of the MAb 8G7 and MAb
1G8 by Western blotting and IHC of two gastric cancer cell lines.
Our Western blotting analysis showed that MAb 8G7 recognized
a very high molecular weight protein (over 500 kD, which was the
expected size for native MUC4), whereas MAb 1G8 does not show
any immunoreactive bands. The IHC analysis also showed MAb
8G7 positive staining but MAb 1G8 negative staining in the two
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gastric cancer cell lines. MUC4 mRNA was also expressed in the
two gastric cancer cell lines in the present study, as shown in the
previous study analyzing the pancreatic cancer cell lines by RT-
PCR and northen blot analyses [33,34]. Both MAb 8G7 and MAb
1G8 react with human gastric cancer tissues, although the
locations of MUC4/8G7 and MUC4/1G8 expression showed
a marked difference. In gastric cancer tissues, MUC4/8G7 was
expressed mainly in the cytoplasm of the neoplastic cells of pap
and tub, whereas MUC4/1G8 was expressed mainly at the cell
apexes of pap and tub or intracytoplasmic mucin substance of sig.
Since the cytoplasmic expression pattern of MUC4/8G7 is seen
also in pancreatic adenocarcinoma, intrahepatic cholangiocarci-
noma, extra hepatic bile duct carcinoma, lung adenocarcinoma
and oral squamous cell carcinoma [9,10,11,12,13], the intracyto-
plasmic MUC4/8G7 expression pattern in gastric cancer tissues
may be reasonable. In contrast, the linear expression pattern of
MUC4/1G8 along with the cell apexes of gastric cancer tissues
may reflect unknown functions or characteristics of the MUC4b
subunit detected by MAb 1G8 raised against rat epitope [15], as
the present study demonstrated that MUC4/1G8 expression were
related to lymphatic invasion and lymph node metastasis that are
poor prognostic factors even in the early gastric cancer.
Particularly in por2 and sig, the expression rate of MUC4/1G8
was significantly higher than that of MUC4/8G7 or that of
MUC1/DF3. In addition, there was a siginificant correlation
between MUC4/8G7 expression and MUC4/1G8 expression in
the patients examined. Thus, the IHC signal of MUC4/1G8
detected in the gastrectomy specimens may show a significant
meaning of the epitope detected by MAb 1G8, although there was
no reactivity of MUC4/1G8 expression in human gastric cancer
cell lines (SNU-16 and NCI-N87). The epitope detected by MAb
1G8 is an area of interest for future study.
In conclusion, in the present study of early gastric cancers,
MUC4/8G7, MUC4/1G8 and MUC1/DF3 expressions were
observed mainly in well differentiated adenocarcinomas. The
MUC4/8G7 expression was related with lymphatic invasion. The
MUC4/1G8 expression was related with lymphatic invasion and
lymph node metastasis. The MUC1/DF3 expression was related
with lymphatic invasion and venous invasion. The examination of
MUC4 and MUC1 expression in the gastric cancers would
become a useful marker to predict poor prognostic factors related
with vessel invasion, even in the early stage.
Supporting Information
Figure S1 In the non-neoplastic mucosa of the cases with gastric
cancer, MUC4/8G7 was expressed sometimes in the cytoplasm of
surface mucous epithelium, and frequently but weakly in the
cytoplasm of fundic and pyloric glands (A and D). MUC4/1G8
was frequently expressed in the cell apex and cytoplasm of the
surface mucous epithelium, and frequently but weakly in the
cytoplasm of fundic and pyloric glands (B and E), and was seen
constantly at the vascular endothelium. MUC1/DF3 was
sometimes expressed in the surface mucous epithelium, and
always in the fundic glands (particularly intensely at the cell
apexes), but not in the pyloric glands (C and F). Original
magnification6100 (A, B, C),6400 (D, E, F).
(TIF)
Table S1 Detailed number and percentage of positively stained
neoplastic cells using the scoring system.
(DOC)
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